Panalgo, a Norstella company dedicated to revolutionizing healthcare data analytics, is announcing a new venture with partner OM1, a forefront leader in real-world evidence (RWE) insights generation, deep specialty data, and advanced AI healthcare technologies. This latest offering enables Panalgo to host OM1’s PremiOM enriched deep clinical datasets across multiple therapeutic areas and chronic conditions in the IHD Analytics platform.
The announcement coincides with Panalgo’s and OM1’s participation in the DIA 2024 Global Annual Meeting in San Diego, where industry regulators, governments, academics, innovators, and patients will address challenges facing the life sciences community.
The Panalgo and OM1 partnership bundles OM1’s robust suite of autoimmune, dermatologic, neuroscience, and other chronic condition datasets with Panalgo’s industry-leading Instant Health Data Analytics (IHD) platform so healthcare stakeholders can more easily achieve their research objectives with access to deep clinical data sets for a multitude of various chronic conditions. OM1’s PremiOM datasets, enriched with clinical endpoints and outcomes, provide research-ready, regulatory-grade insights to accelerate research and improve decision-making.
“We are excited to work with Panalgo as a strategic partner to provide customers with access to deep multi-source longitudinal data that drives better patient outcomes at an accelerated pace,” said Shawn Bates, Chief Commercial Officer, OM1. “Together, we look forward to transforming real-world data into actionable intelligence to advance patient research and improve standard of care.”
Also Read: Tendo Adds Veteran Healthcare Analytics and Informatics Innovator to Leadership Team
OM1 offers the largest linked longitudinal condition datasets with deep clinical and outcomes data. Datasets include conditions in rheumatology/immunology, respiratory/otolaryngology, dermatology, gastroenterology, mental health/neuroscience, and cardiometabolic therapeutic areas. The readily available productized datasets for licensing and/or research analytics are highly curated, drawn from specialty networks with pre-defined populations, and enriched through endpoint amplification using AI and unstructured clinical data.
Panalgo’s IHD Analytics is the industry-leading self-service, enterprise RWE analytical platform enabling rapid analytics and insights. With no complex programming required, it’s 85% faster than traditional custom programming, with a unique, healthcare-specific data model and extensive library of customizable algorithms, plus integrated machine learning and automated documentation. IHD answers questions in real time by conducting risk evaluations, assessing access to treatment, exploring the impact of regulatory action, and evaluating emergent safety issues. It enables clients to generate evidence for the effectiveness, safety, and value of your treatments more fully.
“We are thrilled to expand our partnership with OM1 and welcome them into our Partner Network. OM1 shares our goals in accelerating RWE generation by breaking barriers in the traditional ways clients access data,” said Erik Maul, Senior Director of Partnerships at Panalgo. “With OM1’s specialized data loaded and ready to go in the IHD Analytics platform, clients can worry less about procurement and setup and get right to their analysis, compounding the value and accelerating the time to meaningful research.”
SOURCE: PRWeb